Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.43 |
| ▸ | IDH2 | P48735 | 3/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5100417 | 0.91 | FABP4 (0.45) | CHRM3CHRM2CHRM1SLC1A3SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL5103685 | 0.89 | MEN1 (0.44) | CHRM3CHRM2CHRM1SLC1A3SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL5105750 | 0.86 | IDH2 (0.41) | IDH2FABP4FABP5 | |
| Trifluoroacetic Acid SCHEMBL5112454 | 0.85 | FABP4 (0.44) | CHRM3IDH2FABP4FABP5 | |
| Trifluoroacetic Acid SCHEMBL5112036 | 0.85 | IDH2 (0.45) | CHRM3CHRM2CHRM1IDH2FABP4 | |
| Trifluoroacetic Acid SCHEMBL5113542 | 0.83 | FABP4 (0.58) | IDH2FABP4FABP5CNR1 | |
| SCHEMBL3902040 | 0.83 | CHRM3 (0.61) | CHRM3CHRM2CHRM1SLC1A3SLC1A2 | |
| SCHEMBL3912448 | 0.82 | CHRM3 (0.50) | CHRM3CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL5099508 | 0.82 | IDH2 (0.46) | CHRM3IDH2CNR1 | |
| SCHEMBL5105567 | 0.82 | MEN1 (0.49) | CHRM3CHRM2CHRM1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711183-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | claimed |
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | claimed |
| EP-1711183-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-10-18 | — | — | EP | claimed |
| WO-2005067537-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-28 | — | — | WO | claimed |
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.